Skip to main content

Table 5 Physician survey results

From: A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization

Question

Summary response

Q1: Knowledge of the Polypill concept

 

It has been hypothesized through a meta-analysis that a daily intake of a so-called Polypill (fixed combination of low dose ACE-I, statin, diuretic and aspirin) for life long may reduce the risk of CVD by more than 80%. These results, according to the hypothesis, are applicable to primary and secondary prevention. In a scale from 1 to 10 where 1 is the least and 10 is the maximum, how do you rate your knowledge about the Polypill?

Mean (SD); Median (Minimum, Maximum)

5.6 (2.2); 6.0 (1.0, 10.0)

Q2: Agreement with Wald & Law on lack of need to routinely monitor CVD risk factors

 

The polypill strategy, as suggested by the authors, does not require routine monitoring or measuring the cardiovascular risk factors (such as blood pressure or cholesterol) in patients receiving the Polypill. This has been rationalized by the notion that CVD risk reduction by the Polypill is independent from the baseline value. In a scale from 1 to 10 where 1 is the least and 10 is the maximum, how do you rate your agreement on not to monitor the CVD risk factors in patients receiving the Polypill?

Mean (SD); Median (Minimum, Maximum)

2.9 (2.4); 2.0(1.0, 10.0)

Q3: Most important factor for prescribing a Polypill

 

What would be the most important factor that determine your decision to prescribe the Polypill:

 
 

N (%)

   Few side effects

11(19.3)

   Degree of CVD risk reduction

28 (49.1)

   Low cost

5 (8.7)

   Others

14 (24.6)

Q4: Acceptability to prescribe the Polypill for PRIMARY CVD prevention

 

If it is documented in a large clinical trial that a daily intake of the Polypill reduces the risk of major CVD in people without established CVD (primary prevention ), will you prescribe it to your patients?

 
 

N (%)

   Yes, definitely

39(67.2)

   Yes, probably

11(19.0)

   No

8 (13.8)

Q5: Acceptability to prescribe the Polypill for SECONDARY CVD prevention

 

If it is documented in a large clinical trial that a daily intake of the Polypill reduces the risk of recurrent cardiovascular event in people with established CVD (secondary prevention) will you prescribe it to your patients?

 
 

N, (%)

   Yes, definitely

50 (86.2)

   Yes, probably

4 (6.9)

   No

4(6.9)